BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17336857)

  • 1. [Myelodysplastic syndromes in adults].
    Beyne-Rauzy O; Laurent G; Adoue D
    Presse Med; 2007 Mar; 36(3 Pt 2):481-91. PubMed ID: 17336857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Myelodysplastic syndromes].
    Solary E; Fontenay M
    Rev Prat; 2010 Dec; 60(10):1408-9, 1412. PubMed ID: 21425540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent advances in the classification and treatment of myelodysplastic syndrome].
    Borbényi Z; Varga G
    Orv Hetil; 2000 May; 141(21):1121-6. PubMed ID: 10876314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myelodysplastic syndromes: preleukemic syndromes].
    Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
    Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in supportive care of myelodysplastic syndromes.
    Gordon MS
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):21-4. PubMed ID: 10530713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
    Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
    Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].
    Wei J; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):305-11. PubMed ID: 18426654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory anemia and the myelodysplastic syndromes.
    Lawrence LW
    Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes.
    Komrokji RS; Bennett JM
    Curr Hematol Rep; 2005 May; 4(3):175-81. PubMed ID: 15865868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative review of classification systems in myelodysplastic syndromes (MDS).
    Bennett JM
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
    Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of myelodysplastic syndromes.
    Beris P; Georgiou G
    Semin Hematol; 2012 Oct; 49(4):287-94. PubMed ID: 23079058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.
    Bacher U; Haferlach C; Kröger N; Schnittger S; Kern W; Wiedemann B; Zander AR; Haferlach T
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):1-11. PubMed ID: 20053328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New WHO classification of myelodysplastic syndromes. The consequences].
    Ugo V
    Pathol Biol (Paris); 2002 May; 50(4):278-82. PubMed ID: 12085674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric myelodysplastic syndromes.
    Rytting ME
    Curr Hematol Rep; 2004 May; 3(3):173-7. PubMed ID: 15087064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.